RMgmDB - Rodent Malaria genetically modified Parasites

Back to search results

Summary

RMgm-1231
Malaria parasiteP. yoelii
Genotype
DisruptedGene model (rodent): PY17X_1421600; Gene model (P.falciparum): PF3D7_1321600; Gene product: phosphodiesterase gamma, putative (PDEgamma; PDEγ)
Transgene
Transgene not Plasmodium: GFP
Promoter: Gene model: PBANKA_1133300; Gene model (P.falciparum): PF3D7_1357100; Gene product: elongation factor 1-alpha (eef1a)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PY17X_1421600; Gene product: phosphodiesterase gamma, putative (PDEgamma)
Phenotype Asexual bloodstage; Sporozoite; Liver stage;
Last modified: 25 July 2022, 12:12
  *RMgm-1231
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 25784701
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. yoelii
Parent strain/lineP. y. yoelii 17XNL
Name parent line/clone Not applicable
Other information parent line
The mutant parasite was generated by
Name PI/ResearcherLakshmanan, V; Kappe, SH
Name Group/DepartmentSeattle Biomedical Research Institute
Name InstituteSeattle BioMed
CitySeattle, Washington
CountryUSA
Name of the mutant parasite
RMgm numberRMgm-1231
Principal namepdeγ(-)
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageSlightly reduced growth rate of blood stages
Gametocyte/GameteNot different from wild type
Fertilization and ookineteNot different from wild type
OocystNot different from wild type
SporozoiteNormal number of oocyst-derived sporozoites are produced. In contrast, salivary gland sporozoite numbers in pdeγ(-) infected mosquitoes were ~55-fold lower than in wild type infected mosquitoes.
Sporozoites show a strongly reduced gliding motility
Liver stageNormal number of oocyst-derived sporozoites are produced. In contrast, salivary gland sporozoite numbers in pdeγ(-) infected mosquitoes were ~55-fold lower than in wild type infected mosquitoes.
Sporozoites show a strongly reduced gliding motility
No liver infection after infection of mice by mosquito bite. After intravenous injection of large numbers of sporozoites a low percentage of mice develop blood stage infections (with prolonged prepatent periods)
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of PDEγ and expresses GFP under the control of the constitutive eef1a promoter

Protein (function)
The cyclic nucleotides cAMP and cyclic GMP (cGMP) function as signaling second messengers downstream of surface receptor-ligand interactions by activating cAMP-dependent protein kinase (PKA) and cGMP-dependent protein kinase (PKG), respectively. Signaling through cAMP and cGMP is regulated by phosphodiesterases (PDEs), metal ion-dependent enzymes that hydrolyze the 3"-phosphoester bond of cAMP and cGMP. The Plasmodium genome encodes four PDEs (α, β, γ, and δ).
PDEγ is predicted to be a 782-amino-acid type II membrane protein with six transmembrane domains. A search for the presence of domains using the PDE sequence on Prosite (http://prosite.expasy.org/) predicted the protein to possess the conserved catalytic domain amino acid signature H-D-I-g-H-f-G-r-t-N-m-F for PDEs

Phenotype
Blood stages of the mutant show a slightly reduced growth rate.
Strongly reduced numbers of salivary gland sporozoites while normal numbers of oocyst-derived sporozoites are formed indicating a defect in invasion of salivary glands. Sporozoites show a strongly reduced gliding motility. Evidence is presented that pdeγ(-) sporozoites exhibit elevated cGMP levels and that transcript abundance for proteins involved in motility and invasion is downregulated in pdeγ(-) sporozoites.

Additional information
A blood stage growth assay was performed to determine whether there was a difference in the kinetics of growth between wild-type (WT) and pdeγ(-) parasites. Swiss Webster (SW) mice were injected intravenously (i.v.) with WT and pdeγ(-) clones, and parasitemia was analyzed daily by microscopic examination of Giemsa-stained thin blood smears for 20 days. Parasitemias were comparable between WT and both pdeγ(-) clones during the initial phase of BS growth (from days 1 through 9). However, WT and pdeγ(-) parasites differed in growth kinetics from days 10 through 15. The peak average parasitemia in mice infected with WT parasites was ~16%, which was ~2-fold higher than the peak average parasitemia of ~8% in mice infected with the pdeγ(-) clones. During later stages of growth (day 12 onward), the pdeγ(-) clones were cleared from mice earlier than WT parasites. These data show that PDE is not essential for BS parasite growth and replication.

Other mutants


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PY17X_1421600
Gene Model P. falciparum ortholog PF3D7_1321600
Gene productphosphodiesterase gamma, putative
Gene product: Alternative namePDEgamma; PDEγ
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationP. yoelii 17XNL genomic DNA was used to amplify a 658-bp fragment of the 3'-untranslated region (UTR) using oligonucleotide primers 5' GCGAGCTCGGTACCTATGCGTATAATATTATATGAATAAGAC (sense)
and 5' CATGATATATAACCCTGCAGGTTAACTTGTTTTTATGGAAATTTAAAACC (antisense) and a 566-bp fragment of the 5' UTR with primers 5' CATAAAAACAAGTTAACCTGCAGGGTTATATATCATGGAATTTCGTTGCAC (sense) and 5' ATGCGGCCGCTATCGTTTGACACGAATAAATTTAATCG (antisense) of P. yoelii PDEγ (PyPDEγ). The two PCR products were fused by sequence overlap extension PCR (SOE PCR). The SOE PCR product was cloned into pCR-Blunt (Life Technologies), sequenced, digested with KpnI and NotI, gel purified using a gel extraction kit (Qiagen), and cloned into a modified version of plasmid pL0005 (MR4: MRA-774) ontaining GFPmut2 under the control of the
constitutive P. berghei elongation factor 1 alpha promoter. The final plasmid was linearized with SbfI. Transfection of P. yoelii 17XNL parasites using the Amaxa Nucleofector device (Lonza) and selection of resistant parasites were conducted as previously described
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameGFP
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modification
Additional remarks selection procedure
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1133300
Gene Model P. falciparum ortholog PF3D7_1357100
Gene productelongation factor 1-alpha
Gene product: Alternative nameeef1a
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PY17X_1421600
Gene productphosphodiesterase gamma, putative
Gene product: Alternative namePDEgamma
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4